Milan, 24th February 2020 – Società Italiana per le Imprese all’Estero – SIMEST S.p.A. (SIMEST) has today become a minority shareholder of Kedrion Biopharma Inc. (Kedrion Biopharma) with a stake of 4.5% by means of payment of a capital increase of Kedrion Biopharma of USD equivalent of Euro 10 million.
Kedrion S.p.A. (Kedrion) will hold the remaining stake of 95.5% of Kedrion Biopharma’s share capital.
The entry of the new shareholder and the capital increase contributions from SIMEST will allow Kedrion Biopharma to pursue its development strategy on a national and international level and make the company more attractive for new forms of funding.
Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Kedrion Biopharma, a U.S. subsidiary of Kedrion, is headquartered in Fort Lee, New Jersey. Kedrion launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products.
For further information, please contact [email protected]